In The News
In the News: Six-year-old’s death leads to hope of new drug for childhood cancer
Our collaborator Dr Chris Jones and his fantastic team at The Institute of Cancer Research were profiled in The Observer for their work on DIPG with support from Abbie's Army. M4K Pharma is proud to [...]
Study published on new drug class targeting ACVR1 mutation for DIPG
Study published on new drug class targeting ACVR1 mutation for DIPG Scientists at The Institute of Cancer Research, London, along with colleagues at the Structural Genomics Consortium in Oxford, have published their findings on a new drug [...]
For Innovation, Open Science Means Open for Business
Richard Gold (McGill University) and Max Morgan (SGC, M4k Pharma) penned an opinion piece in the Globe and Mail discussing how open science projects with no patents can result in local economic development, citing the [...]
Can an open drug discovery model find a solution for rare brain cancers in children?
Can an open drug discovery model find a solution for rare brain cancers in children? Dr. Aled Edwards OICR-funded drug discovery project’s unique ‘open science’ business model is accelerating the search for a solution to [...]
Reaction Biology Joins the Fight Against DIPG with M4K Pharma [News Release]
Reaction Biology Joins the Fight Against DIPG with M4K Pharma [News Release] Malvern, PA- May 23, 2018. Reaction Biology Corporation (“RBC”), a leading contract research organization providing early stage drug discovery services, announced that [...]
[Podcast] Bio2040 interviews M4K Pharma’s Owen Roberts
[Podcast] Bio2040 interviews M4K Pharma's Owen Roberts In a podcast interview with Bio2040, CEO Owen Roberts discusses M4K Pharma's business model and why open science and sharing can be the path to finding [...]